Comparison between Mankind Pharma IPO and Signatureglobal IPO.
Mankind Pharma IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while Signatureglobal IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Mankind Pharma IPO is up to ₹4,326.36 Cr whereas the issue size of the Signatureglobal IPO is up to ₹730.00 Cr. The final issue price of Mankind Pharma IPO is ₹1,080.00 per share and of Signatureglobal IPO is ₹385.00 per share.
| Mankind Pharma IPO | Signatureglobal IPO | |
|---|---|---|
| Face Value | ₹1 per share | ₹1 per share |
| Issue Price (Lower) | ₹1,026.00 per share | ₹366.00 per share |
| Issue Price (Upper) | ₹1,080.00 per share | ₹385.00 per share |
| Issue Price (Final) | ₹1,080.00 per share | ₹385.00 per share |
| Discount (Retail) | ₹0.00 per share | ₹0.00 per share |
| Discount (Employee) | ||
| Market Lot Size | 13 shares | 38 shares |
| Fresh Issue Size | 0 shares | 1,56,62,337 shares |
| Fresh Issue Size (Amount) | up to ₹0.00 Cr | up to ₹603.00 Cr |
| OFS Issue Size | 4,00,58,844 shares | 32,98,701 shares |
| OFS Issue Size (Amount) | up to ₹4,326.36 Cr | up to ₹127.00 Cr |
| Issue Size Total | 4,00,58,844 shares | 1,89,61,038 shares |
| Issue Size Total (Amount) | up to ₹4,326.36 Cr | up to ₹730.00 Cr |
Mankind Pharma IPO opens on Apr 25, 2023, while Signatureglobal IPO opens on Sep 20, 2023. The closing date of Mankind Pharma IPO and Signatureglobal IPO is Apr 27, 2023, and Sep 22, 2023, respectively.
| Mankind Pharma IPO | Signatureglobal IPO | |
|---|---|---|
| Anchor Bid Date | Apr 24, 2023 | Sep 18, 2023 |
| Issue Open | Apr 25, 2023 | Sep 20, 2023 |
| Issue Close | Apr 27, 2023 | Sep 22, 2023 |
| Basis Of Allotment (Tentative) | May 03, 2023 | Sep 27, 2023 |
| Initiation of Refunds (Tentative) | May 04, 2023 | Sep 29, 2023 |
| Credit of Share (Tentative) | May 05, 2023 | Oct 03, 2023 |
| Listing date (Tentative) | May 09, 2023 | Sep 27, 2023 |
| Anchor Lockin End date 1 | Jun 02, 2023 | Oct 27, 2023 |
| Anchor Lockin End date 2 | Aug 01, 2023 | Dec 26, 2023 |
Mankind Pharma IPO P/E ratio is 32.5, as compared to Signatureglobal IPO P/E ratio of .
| Mankind Pharma IPO | Signatureglobal IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)
| Company Financials (Restated Consolidated)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 79.00 | 78.36 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 76.50 | 69.63 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 32.5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹43263.60 Cr. | ₹5409.66 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 27.60% | -134.0% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 26.10% | 1% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 34.10 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹33.20 | ₹-5.44 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 27.70% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Mankind Pharma IPO Retail Individual Investors (RII) are offered 1,40,20,596 shares while in Signatureglobal IPO retail investors are offered 1,40,20,596 shares. Qualified Institutional Buyers (QIB) are offered 80,11,769 shares in Mankind Pharma IPO and 59,48,080 shares in Signatureglobal IPO.
| Mankind Pharma IPO | Signatureglobal IPO | |
|---|---|---|
| Anchor Investor Reservation | 1,20,17,652 shares | 82,72,700 shares |
| Market Maker Reservation | ||
| QIB | 80,11,769 shares | 59,48,080 shares |
| NII | 60,08,827 shares | 28,44,155 shares |
| RII | 1,40,20,596 shares | 18,96,103 shares |
| Employee | ||
| Others | ||
| Total | 4,00,58,844 shares | 1,89,61,038 shares |
Mankind Pharma IPO subscribed 15.32x in total, whereas Signatureglobal IPO subscribed 12.50x.
| Mankind Pharma IPO | Signatureglobal IPO | |
|---|---|---|
| QIB (times) | 49.16x | 13.37x |
| NII (times) | 3.80x | 14.24x |
| Big NII (times) | 4.99x | 16.60x |
| Small NII (times) | 1.41x | 9.53x |
| RII (times) | 0.92x | 7.17x |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 15.32x | 12.50x |
